Naniniwala ang mga doktor sa Philippine General Hospital (PGH) na kailangang sumailalim sa karagdagang pagsusuri ang bakuna laban sa COVID-19 na gawa ng Chinese firm na Sinovac.
Ayon sa PGH Physician’s Association, ang appraisal ay dapat na gawin ng Health Technology Assessment Council (HTAC), isang advisory body na siyang sumusuri sa presyo, ethics, at epekto sa komunidad ng isang anti-COVID-19 drug.
“The PGH PA stands firm that Sinovac, despite being the only vaccine available at hand, should undergo appraisal by the Health Technology Assessment Council (HTAC) to facilitate individual informed decision-making before it is administered to healthcare workers. We trust that HTAC shall formulate these recommendations with judicious haste,” saad sa pahayag.
“As the national university hospital, PGH should set an example on how vaccination roll-out should be executed in the country. PGH should uphold the ideals of ethical and evidence-based medicine, for which it has been a bastion of. This should be achieved with constant information dissemination and internal consultation of all concerned parties,” dagdag nito.
Hinimok din ng doctors’ group ang publiko na maging mapagmatyag sa COVID-19 vaccination program ng pamahalaan.
“Let us not lose sight of critical thinking especially with matters relating to our own health by monitoring updates and developments in the COVID-19 vaccination. Public vigilance is key,” dagdag nito.
Una nang sinabi ng HTAC, na binubuo ng mga health experts mula sa iba’t ibang sektor, na hindi pa sumasailalim sa kanilang assessment ang Sinovac vaccines dahil ito ay donated at hindi binili ng gobyerno.
Inirekomenda na rin ng Inter Agency Task Force for Emerging Infectious Diseases ang Sinovac para iturok sa mga health workers.
Ang nasabing bakuna umano ay 50% epektibo sa mild symptoms at 100% sa moderate at severe symptoms.
